Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2021

View Archived Issues

Cyclin C controls responses to PARP inhibitor treatment in BRCA2-deficient cells

LSD1 as potential therapeutic target in heart failure

Antibe places its AME study of otenaproxesul on required pause

First patient dosed in a phase I study of ARX-517

CytomX Therapeutics describes auristatin-related compounds

New PD-1/PD-L1 interaction inhibitors synthesized at Abbisko Therapeutics

Bristol Myers Squibb patents CD80/PD-L1 and/or PD-1/PD-L1 interaction inhibitors

Disarm Therapeutics discovers NAD(+) hydrolase SARM1 inhibitors

ALZ-201 neutralizes the neurotoxicity of postmortem brain extracts from patients with AD

Serum miRNA451a levels are increased in Alzheimer's disease patients

Telmisartan reduces morbidity and mortality in hospitalized patients with COVID-19

ALG-1007 study meets all primary and secondary endpoints

Nordic Nanovector resets expected timeline for phase IIb PARADIGME study of Betalutin

U.S. phase II dosing begins with LUT-014 to reduce EGFR inhibitor-induced acneiform lesions

Phase IIb study of eliapixant in refractory chronic cough meets primary efficacy outcome

Phase I/II trial cleared to begin in Singapore with ARCT-154 and ARCT-165 for SARS-CoV-2

Lumosa reports phase IIa data on LT-3001 in patients after acute ischemic stroke

FDA clears IND for phase Ib study of camsirubicin in advanced soft tissue sarcoma

GTB-5550 TriKE promotes NK cell killing in preclinical testing

South Korea's MFDS clears IND for phase I study of ABL-501 in solid tumors

Phase IIb/III ALLEGRO trial of ritlecitinib in alopecia areata meets primary efficacy endpoint

New study is both reality check and shot in the arm for SARS-CoV-2 drug repurposing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...